tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).
Denise A. Yardley
No relevant relationships to disclose
Adam Brufsky
No relevant relationships to disclose
Robert E. Coleman
No relevant relationships to disclose
Pier Franco Conte
No relevant relationships to disclose
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Stefan Glück
Consultant or Advisory Role - AAIPharma; Agendia; Amgen; Celgene; DARA BioSciences; Eisai; EMD Serono; Genentech; GlaxoSmithKline; Novartis; Onyx; Pfizer
Research Funding - AAIPharma; Agendia; Amgen; Celgene; DARA BioSciences; Eisai; EMD Serono; Genentech; GlaxoSmithKline; Novartis; Onyx; Pfizer
Jean-Marc A. Nabholtz
No relevant relationships to disclose
Joyce O'Shaughnessy
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Eisai; Genentech; GlaxoSmithKline; Johnson & Johnson; Roche; Sanofi
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Eisai; Genentech; GlaxoSmithKline; Johnson & Johnson; Roche; Sanofi
Li Li
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Debora Barton
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Robert M. Beck
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Nadia Harbeck
Consultant or Advisory Role - Celgene; Roche
Honoraria - Celgene; Novartis; Roche
Research Funding - Amgen; Celgene; Roche; Teva